{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:49:10Z","timestamp":1778939350019,"version":"3.51.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Primary melanocytic tumors of the CNS are extremely rare conditions, encompassing different disease processes including meningeal melanoma and meningeal melanocytosis. Its incidence range between 3-5%, with approximately 0.005 cases per 100,000 people. Tumor biological behavior is commonly aggressive, with poor prognosis and very low survivability, and a high recurrence rate, even after disease remission with multimodal treatments. Specific genetic alterations involving gene transcription, alternative splicing, RNA translation, and cell proliferation are usually seen, affecting genes like BRAF, TERT, GNAQ, SF3B1, and EIF1AX. Here we present an interesting case of a 59-year-old male presenting with neurologic symptoms and a further confirmed diagnosis of primary meningeal melanoma. Multiple therapy lines were used, including radiosurgery, immunotherapy, and chemotherapy. The patient developed two relapses and an evolving genetic makeup that confirmed the disease\u2019s clonal origin. We also provide a review of the literature on the genetic basis of primary melanocytic tumors of the CNS.<\/jats:p>","DOI":"10.3389\/fonc.2021.691017","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T04:57:38Z","timestamp":1641358658000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Case Report: Differential Genomics and Evolution of a Meningeal Melanoma Treated With Ipilimumab and Nivolumab"],"prefix":"10.3389","volume":"11","author":[{"given":"Remberto","family":"Burgos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s F.","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Santoyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Ruiz-Pati\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juanita","family":"Cure-Casilimas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Ricaurte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Esteban","family":"Garcia-Robledo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila","family":"Ordo\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Sotelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"July","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zyanya Lucia","family":"Zatarain-Barr\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Arrieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s10014-018-0308-1","article-title":"Whole-Exome Sequencing of a Meningeal Melanocytic Tumour Reveals Activating CYSLTR2 and EIF1AX Hotspot Mutations and Similarities to Uveal Melanoma","volume":"35","author":"K\u00fcsters-Vandevelde","year":"2018","journal-title":"Brain Tumor Pathol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.yexmp.2016.12.006","article-title":"Copy Number Variation Analysis and Methylome Profiling of a GNAQ-Mutant Primary Meningeal Melanocytic Tumor and Its Liver Metastasis","volume":"102","author":"K\u00fcsters-Vandevelde","year":"2017","journal-title":"Exp Mol Pathol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40478-016-0272-0","article-title":"SF3B1 and EIF1AX Mutations Occur in Primary Leptomeningeal Melanocytic Neoplasms; Yet Another Similarity to Uveal Melanomas","volume":"4","author":"K\u00fcsters-Vandevelde","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"B4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/s12885-016-2556-y","article-title":"NRASQ61K Mutated Primary Leptomeningeal Melanoma in a Child: Case Presentation and Discussion on Clinical and Diagnostic Implications","volume":"16","author":"Angelino","year":"2016","journal-title":"BMC Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw134","article-title":"Targeted Treatment and Immunotherapy in Leptomeningeal Metastases From Melanoma","volume":"27","author":"Geukes Foppen","year":"2016","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"dju267","DOI":"10.1093\/jnci\/dju267","article-title":"The Effect on Melanoma Risk of Genes Previously Associated With Telomere Length","volume":"106","author":"Iles","year":"2014","journal-title":"JNCI J Natl Cancer Inst"},{"key":"B7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent Somatic Mutations of GNAQ in Uveal Melanoma and Blue Naevi","volume":"457","author":"Van Raamsdonk","year":"2009","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in Uveal Melanoma","volume":"363","author":"Van Raamsdonk","year":"2010","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12444","article-title":"A Primary Melanoma and Its Asynchronous Metastasis Highlight the Role of BRAF, CDKN2A, and TERT","volume":"42","author":"Hosler","year":"2015","journal-title":"J Cutan Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12652","article-title":"Leptomeningeal Melanoma\u2014A Case Series in the Era of Modern Systemic Therapy","volume":"31","author":"Arasaratnam","year":"2018","journal-title":"Pigment Cell Melanoma Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/pcmr.12843","article-title":"GNAQQ209L Expression Initiated in Multipotent Neural Crest Cells Drives Aggressive Melanoma of the Central Nervous System","volume":"33","author":"Urtatiz","year":"2020","journal-title":"Pigment Cell Melanoma Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jmedgenet-2015-103150","article-title":"Melanoma Genetics","volume":"53","author":"Read","year":"2016","journal-title":"J Med Genet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/cyt.12366","article-title":"CSF Cytology Diagnosis of NRAS-Mutated Primary Leptomeningeal Melanomatosis With Neurocutaneous Melanosis","volume":"28","author":"Kolin","year":"2017","journal-title":"Cytopathology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/neup.12443","article-title":"Intraventricular Melanocytoma Diagnosis Confirmed by Gene Mutation Profile","volume":"38","author":"Knappe","year":"2018","journal-title":"Neuropathol Off J Jpn Soc Neuropathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0763","article-title":"Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling","volume":"24","author":"Griewank","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/science.1230062","article-title":"TERT Promoter Mutations in Familial and Sporadic Melanoma","volume":"339","author":"Horn","year":"2013","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/science.1229259","article-title":"Highly Recurrent TERT Promoter Mutations in Human Melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1038\/ncomms4401","article-title":"Telomerase Reverse Transcriptase Promoter Mutations in Primary Cutaneous Melanoma","volume":"5","author":"Heidenreich","year":"2014","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-2878-5","article-title":"Leptomeningeal Disease in Uveal Melanoma: A Case Series","volume":"139","author":"Glitza","year":"2018","journal-title":"J Neurooncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e000283","DOI":"10.1136\/esmoopen-2017-000283","article-title":"Retrospective Review of Metastatic Melanoma Patients With Leptomeningeal Disease Treated With Intrathecal Interleukin-2","volume":"3","author":"Glitza","year":"2018","journal-title":"ESMO Open"},{"key":"B21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ctrv.2017.08.009","article-title":"Immune Checkpoint Blockade for Unresectable or Metastatic Uveal Melanoma: A Systematic Review","volume":"60","author":"Heppt","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00037","article-title":"Ocular Immune Privilege and Transplantation","volume":"7","author":"Taylor","year":"2016","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e000960","DOI":"10.1136\/jitc-2020-000960","article-title":"Immune Profiling of Uveal Melanoma Identifies a Potential Signature Associated With Response to Immunotherapy","volume":"8","author":"Qin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02773-8","article-title":"Prognostic Significance of PD-1\/PD-L1 Expression in Uveal Melanoma: Correlation With Tumor-Infiltrating Lymphocytes and Clinicopathological Parameters","volume":"70","author":"Singh","year":"2021","journal-title":"Cancer Immunol Immunother CII"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e22928","DOI":"10.1097\/MD.0000000000022928","article-title":"Primary Leptomeningeal Melanomatosis Successfully Treated With PD-1 Inhibitor Pembrolizumab: A Case Report","volume":"99","author":"Misir Krpan","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7150\/thno.47983","article-title":"Immunomodulation of Intracranial Melanoma in Response to Blood-Tumor Barrier Opening With Focused Ultrasound","volume":"10","author":"Curley","year":"2020","journal-title":"Theranostics"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6096","article-title":"Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma: A Randomized Clinical Trial","volume":"311","author":"Carvajal","year":"2014","journal-title":"JAMA"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.1090","article-title":"Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)","volume":"36","author":"Carvajal","year":"2018","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.9511","article-title":"A Randomized Phase 2 Study of Trametinib With or Without GSK2141795 in Patients With Advanced Uveal Melanoma","volume":"34","author":"Shoushtari","year":"2016","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3390\/cancers11060834","article-title":"Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope","volume":"11","author":"Castet","year":"2019","journal-title":"Cancers"},{"key":"B31","doi-asserted-by":"publisher","first-page":"9511","DOI":"10.1200\/JCO.2017.35.15_suppl.9511","article-title":"STREAM: A Randomized Discontinuation, Blinded, Placebo-Controlled Phase II Study of Sorafenib (S) Treatment of Chemona\u00efve Patients (Pts) With Metastatic Uveal Melanoma (MUM)","volume":"35","author":"Scheulen","year":"2017","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12861","article-title":"Leptomeningeal Disease in Melanoma Patients: An Update to Treatment, Challenges, and Future Directions","volume":"33","author":"Glitza","year":"2020","journal-title":"Pigment Cell Melanoma Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.691017\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T04:57:41Z","timestamp":1641358661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.691017\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,5]]},"references-count":32,"alternative-id":["10.3389\/fonc.2021.691017"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.691017","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,5]]},"article-number":"691017"}}